Zai Lab gets two new listings on China's 2026 reimbursement drug list
Five Zai Lab medicines were added to China's 2026 National Reimbursement Drug List, which takes effect on January 1, 2027, per TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, five Zai Lab medicines have been included in China's 2026 National Reimbursement Drug List. KarXT and VYVGART Hytrulo are being listed for the first time, while three other products have been renewed.
The new list takes effect on January 1, 2027. Reimbursement will widen patient access to the two new products, but the announcement gives no revenue figures or pricing terms.
why it matters
This is an update on commercial access to products the company already markets, not a new clinical or financial result. The effect on sales will depend on how quickly doctors and patients use these medicines once the list takes effect, and that data is not yet available.
tags
instruments
sources
- Zai Lab Limited Adds Two Products to China’s 2026 Reimbursement List — TradingView, 14 November 2026 at 03:26 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗